- Combined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC). Daniel Bsteh, Jonathan Buckley, Scott Mitchell, et al. Journal of Clinical Oncology. Volume 43, Number 16_suppl. Meeting Abstract: 2025 ASCO Annual Meeting. May 28, 2025
- (Download PDF)
-
Products
Sectors
Categories
Product Information
- How to order
- [Flyer] MiniMax cfDNA Extraction & Automation (PDF)
- [Flyer] MiniMax cfRNA Extraction Solutions (PDF)
- [Flyer] MiniGenomics genomic DNA Isolation & Automation (PDF)
- [Flyer] MiniGenomics total RNA Isolation & Automation (PDF)
- [Flyer] miniEnrich DNA Purification & Size Selection Beads (PDF)
-
Technology
- Apostle MiniMax Technology (cfDNA)
- Apostle MiniMax Technology (cfRNA)
- Apostle MagTouch Technology
- Apostle BCT Technology
- Apostle MiniEnrich Technology
- Apostle MiniGenomics Technology
- Apostle MiniGenomics Technology (Stool)
- Apostle Triton Technology
- Apostle MiniMax (Type S)
- Apostle Viral RNA/DNA Isolation Automation System
- Apostle Well Plates and Accessories for Nucleic Acids Isolation
- How to choose a -86°C ULT Freezer
-
Applications
- Applications of Apostle Technologies
- By Therapeutic Areas or Methods
- Oncology
- NIPT (Noninvasive Prenatal Testing)
- Cerebrospinal Fluid (CSF)
- Virology & Public Health
- Cardiovascular Research
- NGS (Next-Gen Sequencing)
- DNA Methylation Analysis
- cfRNA Analysis
- ddPCR (Droplet Digital PCR)
- rtPCR (Real Time PCR)
- cfChIP (cell-free Chromatin Immunoprecipitation)
- Clinical Trial
- Sign In